Literature DB >> 10870986

The stereoselective distribution of halofantrine enantiomers within human, dog, and rat plasma lipoproteins.

D R Brocks1, M Ramaswamy, A I MacInnes, K M Wasan.   

Abstract

PURPOSE: To study the in vitro distribution of the enantiomers of the antimalarial drug halofantrine in human, dog and rat plasma lipoprotein-fractions.
METHODS: Plasma was spiked with racemic halofantrine (1,000 ng/ml) and incubated for 1 h at 37 degree C. The fractions (high and low density lipoproteins, triglyceride-rich lipoproteins and lipoprotein deficient plasma) were separated using density gradient ultracentrifugation. Fractions were assayed for halofantrine enantiomer using stereospecific high performance liquid chromatography.
RESULTS: The (-) enantiomer of halofantrine displayed higher affinity for the lipoprotein-deficient fraction than the (+) enantiomer in all three species. The (+) enantiomer was predominately located in the lipoprotein rich fractions of dog and human plasma (the (+):(-) ratio ranging from 1.2-9.6). In contrast, the (+):(-) ratio was consistently < 1 in lipoprotein-deficient fractions. Dog displayed a large magnitude of stereoselectivity in halofantrine distribution to the plasma fractions tested. There were substantial interspecies differences in the pattern of distribution of halofantrine enantiomers within the different fractions. A significant positive relationship was observed between halofantrine uptake into lipoprotein-rich fractions and the percent of apolar core lipid in those fractions. There was also a strong negative correlation between total protein concentration and the enantiomeric ratio in the lipoprotein-deficient plasma fraction.
CONCLUSION: Distribution of halofantrine enantiomer to plasma lipoprotein-fractions is stereoselective and species specific. This differential binding of halofantrine enantiomers to lipoproteins may need to be considered in viewing pharmacokinetic and pharmacodynamic data involving the drug.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10870986     DOI: 10.1023/a:1007524919865

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  19 in total

1.  In vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline against Plasmodium falciparum.

Authors:  L K Basco; C Gillotin; F Gimenez; R Farinotti; J Le Bras
Journal:  Br J Clin Pharmacol       Date:  1992-05       Impact factor: 4.335

2.  A comparison of step-gradient and sequential density ultracentrifugation and the use of lipoprotein deficient plasma controls in determining the plasma lipoprotein distribution of lipid-associated nystatin and cyclosporine.

Authors:  K M Wasan; S M Cassidy; M Ramaswamy; A Kennedy; F W Strobel; S P Ng; T Y Lee
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

Review 3.  Stereochemical aspects of pharmacotherapy.

Authors:  D R Brocks; F Jamali
Journal:  Pharmacotherapy       Date:  1995 Sep-Oct       Impact factor: 4.705

4.  Plasmodium falciparum: role of absolute stereochemistry in the antimalarial activity of synthetic amino alcohol antimalarial agents.

Authors:  J M Karle; R Olmeda; L Gerena; W K Milhous
Journal:  Exp Parasitol       Date:  1993-06       Impact factor: 2.011

5.  The antimalarial drug halofantrine is bound mainly to low and high density lipoproteins in human serum.

Authors:  B Cenni; J Meyer; R Brandt; B Betschart
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

6.  X-ray crystal structure of the antimalarial agent (-)-halofantrine hydrochloride supports stereospecificity for cardiotoxicity.

Authors:  J M Karle
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

7.  Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state.

Authors:  A J Humberstone; C J Porter; G A Edwards; W N Charman
Journal:  J Pharm Sci       Date:  1998-08       Impact factor: 3.534

8.  A liquid chromatographic assay for the stereospecific quantitative analysis of halofantrine in human plasma.

Authors:  D R Brocks; M J Dennis; W H Schaefer
Journal:  J Pharm Biomed Anal       Date:  1995-06       Impact factor: 3.935

Review 9.  Clinical pharmacokinetics of halofantrine.

Authors:  J Karbwang; K Na Bangchang
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

10.  Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria.

Authors:  S Krishna; F ter Kuile; W Supanaranond; S Pukrittayakamee; P Teja-Isavadharm; D Kyle; N J White
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

View more
  3 in total

Review 1.  Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems.

Authors:  Marilyn N Martinez
Journal:  AAPS J       Date:  2011-10-05       Impact factor: 4.009

Review 2.  Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs.

Authors:  Dion R Brocks; Reza Mehvar
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Analysis of lipoprotein profiles of healthy cats by gel-permeation high-performance liquid chromatography.

Authors:  Hisashi Mizutani; Toshinori Sako; Hiroko Okuda; Nobuaki Arai; Koji Kuriyama; Akihiro Mori; Itaru Yoshimura; Hidekazu Koyama
Journal:  J Vet Med Sci       Date:  2016-05-07       Impact factor: 1.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.